Iron Oxide Nanoparticles Inhibit Tumor Progression and Suppress Lung Metastases in Mouse Models of Breast Cancer
Authors:
Open Access
- 2 April 2024
- journal article
- research article
- Published by American Chemical Society (ACS) in ACS Nano
- Vol. 18 (15) , 10509-10526
Abstract
Systemic exposure to starch-coated iron oxide nanoparticles (IONPs) can stimulate antitumor T cell responses, even when little IONP is retained within the tumor. Here, we demonstrate in mouse models of metastatic breast cancer that IONPs can alter the host immune landscape, leading to systemic immune-mediated disease suppression. We report that a single intravenous injection of IONPs can inhibit primary tumor growth, suppress metastases, and extend survival. Gene expression analysis revealed the activation of Toll-like receptor (TLR) pathways involving signaling via Toll/Interleukin-1 receptor domain-containing adaptor-inducing IFN-β (TRIF), a TLR pathway adaptor protein. Requisite participation of TRIF in suppressing tumor progression was demonstrated with histopathologic evidence of upregulated IFN-regulatory factor 3 (IRF3), a downstream protein, and confirmed in a TRIF knockout syngeneic mouse model of metastatic breast cancer. Neither starch-coated polystyrene nanoparticles lacking iron, nor iron-containing dextran-coated parenteral iron replacement agent, induced significant antitumor effects, suggesting a dependence on the type of IONP formulation. Analysis of multiple independent clinical databases supports a hypothesis that upregulation of TLR3 and IRF3 correlates with increased overall survival among breast cancer patients. Taken together, these data support a compelling rationale to re-examine IONP formulations as harboring anticancer immune (nano)adjuvant properties to generate a therapeutic benefit without requiring uptake by cancer cells.Keywords
Funding Information
- Jayne Koskinas Ted Giovanis Foundation for Health and Policy
This publication has 56 references indexed in Scilit:
- A New Landscape of Testing and Therapeutics in Metastatic Breast CancerClinics In Laboratory Medicine, 2023
- Why nanoparticles prefer liver macrophage cell uptake in vivoAdvanced Drug Delivery Reviews, 2022
- Survival analysis across the entire transcriptome identifies biomarkers with the highest prognostic power in breast cancerComputational and Structural Biotechnology Journal, 2021
- Recent clinical trends in Toll‐like receptor targeting therapeuticsMedicinal Research Reviews, 2018
- Ferroptosis: A Regulated Cell Death Nexus Linking Metabolism, Redox Biology, and DiseaseCell, 2017
- Internal Magnetic Structure of Nanoparticles Dominates Time‐Dependent Relaxation Processes in a Magnetic FieldAdvanced Functional Materials, 2015
- Physicochemical Characteristics of Nanoparticles Affect Circulation, Biodistribution, Cellular Internalization, and TraffickingSmall, 2012
- Drug targeting to tumors: Principles, pitfalls and (pre-) clinical progressJournal of Controlled Release, 2012
- Hallmarks of Cancer: The Next GenerationCell, 2011
- Toll-like Receptors Activate Innate and Adaptive Immunity by using Dendritic Cell-Intrinsic and -Extrinsic MechanismsImmunity, 2008